Mannkind Stock Drops Following Changes to Its Insulin Product
Mannkind stock is suffering, and the company appears to be in trouble.
Shares of the distressed insulin maker Mannkind (MNKD) - Get Report plummeted nearly 16% Thursday morning following a conference call with investors and analysts. Proposed changes to its Afrezza drug and its sales structure may not produce the results the drugmaker seeks.
This article was written by a staff member of TheStreet.
